IPLTF → $527.00 by Oct 2, 2030.

**Deep Dive: Why Institutional Flows Are Creating a Fundamental Mispricing in a Newly FDA-Approved MedTech Disruptor (OTC: IPLTF)** I’ve spent weeks breaking down a tiny European medtech company called **Implantica (OTC: IPLTF)** that just received FDA PMA approval for its mechanical reflux device, *RefluxStop*. The market is pricing this like a slow, traditional medtech ramp. In reality, the company has an immediate 12-month ROI for U.S. insurance companies against expensive chronic drugs, zero dilution risk for 2027 due to a …